Year archive

Apontis Pharma AG — 2022 filings

All 35 regulatory filings released by Apontis Pharma AG (APPH) in 2022, sourced directly from the official regulator.

35 Filings

2022 Period

2022 filings (35)

Filing	Released	Lang
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021 Audit Report / Information FY 2021	2022-12-14	German
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills Portfolio grows by two in-licensing deals Regulatory Filings	2022-11-29	English
APONTIS PHARMA confirms 2022 forecast after successful nine-month period Strong Single Pill pipeline to achieve medium-term targets Earnings Release 9M 2022	2022-11-10	English
9M Präsentation (EN) Investor Presentation	2022-11-10	German
9M Results Presentation Investor Presentation	2022-11-10	English
APONTIS PHARMA announces cooperation to launch new Single Pill in Germany Regulatory Filings	2022-09-20	English
APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill Regulatory Filings	2022-09-01	English
APONTIS PHARMA expands profitable positioning in first half of 2022 full-year forecast confirmed Earnings Release H1 2022	2022-08-11	English
H122 Results Presentation (EN) Interim / Quarterly Report H2 2022	2022-08-11	German
H122 Results Presentation Interim / Quarterly Report H2 2022	2022-08-11	English
Half-yearly financial statements 2022 Interim / Quarterly Report H2 2022	2022-08-11	English
Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021 Annual Report FY 2021	2022-07-22	German
APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European intellectual property rights Regulatory Filings	2022-07-19	English
APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis Environmental & Social Information	2022-07-06	English
APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052 Transaction in Own Shares	2022-06-23	English
APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million Earnings Release FY 2022	2022-05-25	English
APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities AGM Information	2022-05-12	English
APONTIS PHARMA continues strong profitable growth in Q1 2022 Earnings Release Q1 2022	2022-05-10	English
3M22 Earnings Call Investor Presentation	2022-05-10	English
3M22 Unaudited Results (EN) Investor Presentation	2022-05-10	German
3M22 Unaudited Results Investor Presentation	2022-05-10	English
APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights Regulatory Filings	2022-05-05	English
APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of cardiovascular patients by Single Pill therapy Legal Proceedings Report	2022-04-20	English
Annual financial statements 2021 Annual Report FY 2021	2022-03-30	English
Declaration of Compliance 2021 (German only) Governance Information	2022-03-30	German
Annual financial statements 2021 Annual Report FY 2021	2022-03-30	English
Einzelabschluss 2021 (german only) Audit Report / Information FY 2021	2022-03-30	German
Einzelabschluss 2021 Audit Report / Information FY 2021	2022-03-30	German
APONTIS PHARMA: START study published in scientific journal - Lower incidence of cardiovascular events with Single Pill therapy Regulatory Filings	2022-03-16	English
APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052 Share Issue/Capital Change	2022-03-15	English
APONTIS PHARMA and AstraZeneca extend strategic sales cooperation Regulatory Filings	2022-03-08	English
APONTIS PHARMA reports successful financial year 2021 - Single Pills as growth driver Earnings Release FY 2021	2022-03-03	English
FY21 Preliminary Results (EN) Investor Presentation	2022-03-03	English
FY21 Preliminary Results Investor Presentation	2022-03-03	English
Code of Conduct of the APONTIS PHARMA Group (German only) Governance Information	2022-02-01	German